Subscribe

Lifestyle Enrichment May Have Some Effect on Alzheimer's Disease Biomarkers

VBCN - July 2016 Volume 3, No 2 - Alzheimer’s Disease/Dementia
Laura Morgan

Cognitive enrichment, including intellectual and physical activities, has been shown to delay cognitive impairment; however, its role in the pathophysiology of Alzheimer's disease has yielded contradictory results. A team of researchers from the Mayo Clinic in Rochester, MN, conducted a study on the impact of education on the pathophysiology of Alzheimer's disease (Vemuri P, et al. Neurology. 2016;86:1128-1135).

Discrepancies in Alzheimer's disease biomarker studies regarding lifestyle enrichment can be partly explained by differences between cohorts, sample sizes, and paradigms of enrichment. More important, however, variations in patient education levels may contribute to the conflicting results; education occurs during sensitive periods of brain development, and, therefore, may have a significant impact on Alzheimer's disease biomarker trajectories.

Prashanthi Vemuri, PhD, Assistant Professor of Radiology, Mayo Clinic, and colleagues, followed 393 individuals (aged 70-89 years) with APOE ge­notype and without dementia who had participated in the Mayo Clinic Study of Aging. They used 3 biomarkers to assess the pathophysiology of Alzheimer's disease, including (1) Pittsburgh compound B as an indicator of cerebral amyloidosis, (2) fluorodeoxyglucose (FDG) as an indicator of brain metabolism, and (3) hippocampal volume as an indicator of neurodegeneration.

All the participants completed questionnaires related to education level, primary occupation throughout life, midlife weekly cognitive activity, and physical activity. The results were analyzed in relation to the 3 biomarkers noted above.

Amyloid deposition

Older age and APOE4 status were significantly associated with higher levels of amyloid deposition. In addition, high midlife cognitive activity was associated with lower amyloid deposition in APOE4 carriers with high education, suggesting a link between high cognitive enrichment and low amyloid deposition, especially in highly educated individuals. These results may be attributed to the link between education, APOE4 status, and amyloid deposition, the researchers suggest.

“Higher levels of education and higher levels of midlife cognitive activities somehow forestall amyloid deposition, which is evident in APOE4 carriers because APOE4 carriers are accumulating amyloid at an earlier age and at a faster rate than APOE4 noncarriers,” wrote Dr Vemuri and colleagues.

FDG uptake

Older age and APOE4 gene status were also linked to lower glucose metabolism, a finding consistent with previous studies. Furthermore, this study showed that APOE4 was not associated with lower FDG uptake in highly educated participants, suggesting that “high education in APOE4 carriers may be protective via nonimpaired glucose metabolism,” the authors wrote.

Hippocampal volume

Older age was further linked to lower hippocampal volume, but APOE4 status did not impact hippocampal atrophy trajectories. Overall, enrichment activities did not affect biomarkers of neurodegeneration. Although this finding is contradictory to some previous data, the effect of lifestyle enrichment on neurodegeneration varies, depending on the biomarker used and the disease stage.

Clinical implications

Taken together, these results suggest that lifestyle enrichment variables, including education, occupation, midlife cognitive activity, and midlife physical activity, have some, albeit minimal, impact on Alzheimer's disease, especially on the rate of worsening. Overall, highly educated individuals with the APOE4 genotype and high midlife cognitive activity have lower amyloid deposition than APOE4 carriers with low midlife cognitive activity. Furthermore, age is associated with amyloid and neurodegeneration biomarker trajectories, and APOE4 status affected amyloid and FDG trajectories. Finally, APOE4 status was linked to lower FDG uptake in the entire cohort and in the lower education cohort.

Related Items
Alemtuzumab Reduces Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Reducing the Cost and Improving the Care of Patients with Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Stem-Cell Therapy Reverses Disability in Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Idalopirdine Improves Cognition in Patients with Moderate Alzheimer’s Disease
Chase Doyle
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Alzheimer’s Disease/Dementia
Pro and Con: Do Cognitive-Enhancing Activities Prevent Dementia?
Chase Doyle
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Alzheimer’s Disease/Dementia
Alzheimer’s Prevention Clinic: A New Approach to Disease Management Shows Benefits
Chase Doyle
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Alzheimer’s Disease/Dementia
Osimertinib Effective for First-Line Treatment of EGFR Mutation–Positive NSCLC
Laura Morgan
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Lung Cancer
New Migraine Screening Tool Shows Promise
Laura Morgan
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Migraine
CSF Biomarkers and Amyloid PET Equally Accurate in Identifying Early-Stage Alzheimer’s Disease
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Alzheimer’s Disease/Dementia
BDNF Gene Expression Slows Cognitive Decline in Alzheimer’s Disease
Laura Morgan
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Alzheimer’s Disease/Dementia
Last modified: August 3, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology